After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...